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A 47-year-old man with heterozygous factor V Leiden disorder and intermittent hyperhomocysteinemia developed
spontaneous acute popliteal artery thrombosis. Homocysteine levels were above normal limits at presentation. Intra-
arterial thrombolysis was used successfully to treat the acute thrombosis; long-term treatment included anticoagulation,
folic acid, and risk factor modification. Although factor V Leiden is strongly associated with deep venous thrombosis,
additional cofactors such as hyperhomocysteinemia may predispose to an increased risk of acute arterial thrombosis in
areas of pre-existing peripheral arterial disease. ( J Vasc Surg 2005;42:1014-8.)Factor V Leiden (FVL) is strongly associated with deep
venous thrombosis; however, additional cofactors such as
hyperhomocysteinemia may predispose a patient to an in-
creased risk of acute arterial thrombosis in areas of pre-
existing peripheral arterial disease. We present the case of a
patient with heterozygous factor V Leiden disorder and
intermittent hyperhomocysteinemia who developed spon-
taneous acute popliteal artery thrombosis.
CASE REPORT
A 47-year-old man presented with a one-day history of in-
creasing right leg supramalleolar pain; there was no history of
trauma. His past medical history was significant for hypertension,
hypercholesterolemia, and one-block left leg claudication, but no
history of atrial fibrillation or previous myocardial infarction. He
experienced a stroke 8 years before admission secondary to a
spontaneous right carotid artery dissection, with residual left-sided
weakness.
The patient also had a history of multiple upper- and lower-
extremity venous thrombosis, with upper-extremity deep venous
thrombosis (DVT) first diagnosed in his right arm 8 years before
presentation and saphenous vein thrombosis 2 years before presen-
tation. The work-up at that time determined that the patient was a
heterozygous carrier of the FVL mutation. Test results for muta-
tions of prothrombin gene G20210, protein C or S deficiency, and
antithrombin III deficiency were negative. Serum homocysteine
was 18.31 umol/L (normal, 5 to 15 umol/L). Antibodies for
anticardiolipin and the lupus anticoagulant were not detectable.
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1014The surgical history included an uncomplicated tonsillectomy.
Medications included warfarin, 5 mg once daily, (international
normalized ratio [INR] goal, 2.0 to 2.5), managed at an outpa-
tient anticoagulation clinic; however, compliance was frequently
noted to be poor. The patient continued to smoke one pack of
cigarettes daily.
On physical examination, the right foot was ischemic and cool
to the level of the knee. The left lower extremity was warm and well
perfused. Both femoral pulses were easily palpable. The left popli-
teal, dorsalis pedis, and posterior tibial arteries had biphasic Dopp-
ler signals, but the right popliteal and dorsalis pedis arteries had
monophasic signals, with no signal in the posterior tibial. These
diminished pulses were significantly decreased from his most pre-
viously documented palpable right posterior tibial pulse. The
ankle-brachial index on the right was 0.41 and 0.92 on the left.
The results of a motor and sensory examination of the bilateral
lower extremities were normal. Laboratory data included a pro-
thrombin time of 14.2 seconds, corresponding to an INR of 1.4;
the last INR measurement in the outpatient clinic, 3 months
before this admission, was 2.2.
The patient was admitted with a diagnosis of acute arterial
occlusion and treated with intravenous heparin at 1000 U/h.
Ultrasound examination of his lower extremities failed to reveal
any DVT. Angiography demonstrated thrombus in the distal su-
perficial femoral and popliteal arteries (Fig 1). The thrombus was
crossed with a wire, and catheter-directed thrombolysis was ad-
ministered using tissue plasminogen activator (tPA) (4-mg bolus,
1.5 mg/h for 24 hours, with intra-arterial heparin, 500 U/h).
After 24 hours, the exam results improved, with a biphasic
Doppler signal in both the dorsalis pedis and posterior tibial
arteries. The tPA infusion was continued an additional 24 hours.
Completion angiography, after 48 hours, demonstrated successful
thrombolysis with underlying popliteal and tibial-peroneal trunk
disease (Fig 2). The patient’s hospital course was remarkable for
right leg superficial cellulitis treated with a 10-day course of a
cephalosporin. The patient refused prophylactic placement of an
inferior vena cava filter. He was discharged home on day 8. His
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folic acid. The patient was counseled to quit smoking, given
transdermal nicotine, and referred to our smoking cessation clinic.
DISCUSSION
FVL disorder refers to the point mutation of circulating
plasma factor V, a single-chain, vitamin-K-dependent glyco-
protein made in the liver. The clinical syndrome was first
described in 1993 as activated protein C resistance (APC-R)
syndrome, named after a group of patients with unexplained
venous thromboemboli and abnormal activated partial
thromboplastin time assays.1 Since the identification of the
genetic mutation responsible for APC-R syndrome oc-
curred at the Hemostasis and Thrombosis Research Center
in Leiden, Amsterdam, the condition has been referred to
as factor V Leiden.
Factor V is normally prothrombotic, binding to factor
X to form the prothrombin complex, which in turn acti-
vates factor II to cross-link fibrin complexes. As part of
normal feedback inhibition, factor Va is deactivated by
activated protein C (APC) by cleavage at amino acid 506,
thus limiting the extent of clot formation.
In patients with FVL, factor Va is resistant to deactiva-
tion by APC. The isolated nature of the Leiden defect—a
substitution of adenine for guanine at nucleotide 1691—is
such that the abnormal factor Va is ineffective at limiting
Fig 1. Angiogram of right popliteal artery, initial view.fibrin formation but is enzymatically active in its prothrom-botic capacity. Thus, FVL does not predispose to clot
formation in the absence of other commonly recognized
risk factors such as stasis or endovascular injury.
The patient reported here had a history of smoking,
which is recognized to promote thrombosis, at least in
women.2 Although this patient had a history of peripheral
arterial disease, and peripheral arterial disease may promote
thrombosis, the extent of coronary or peripheral arterial
disease is not clearly associated with either FVL or APC
activity.3-5
FVL typically presents with venous thrombosis, with or
without pulmonary embolism. Thrombosis of deep veins
(57%) is more common than in superficial vessels (43%),
but the distribution is more balanced than that found in
other hypercoagulable disorders.6 In protein C deficiency,
for example, 88% of venous thrombi occur in deep veins. In
antithrombin deficiency, 90% of thrombi form in the deep
veins; in protein C or S deficiency, 99% of thrombi occur
the deep vessels. Given the much greater prevalence of FVL
in relation to these other disorders, the presence of venous
thrombi in superficial vessels might be a useful clinical tool
as part of the hypercoagulable workup.
FVL is also associated with unexplained recurrent loss
of pregnancy, as are several other hypercoagulable disor-
ders, such as the antiphospholipid syndrome.7 It is gener-
Fig 2. Angiogram of right popliteal artery after tissue plasmino-
gen activator infusion.ally believed that this is due to thrombosis of the placental
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preeclampsia, but these data are less established.
Patients with FVL are generally not afforded special
precautions when undergoing surgery. Support for this
practice was established in a 1998 study of 825 subjects
with and without FVL who underwent total hip or knee
replacement.8 Although the absolute incidence of ve-
nous thromboembolism, as diagnosed by venogram, was
higher in FVL patients (31%) than controls (26%), the
authors found no statistically significant association be-
tween FVL and venous thrombosis. More recently, how-
ever, a study of 775 patients undergoing peripheral
vascular surgery found a significant difference in the rate
of postoperative graft occlusion at 1 month (14% vs 7%,
P  .02) and 1 year (22% vs 12%, P  .02).9 Hyperten-
sion, smoking, and pulmonary disease were significantly
more common in patients who did not possess the FVL
mutation. Little research has been published on the
efficacy of coagulation precautions for FVL patients, but
the clear association of FVL and graft occlusion suggests
that it is a worthy area of investigation.
The factor V gene is expressed codominantly. From
90% to 95% of people with the FVL mutation are heterozy-
gotes; the remainder are homozygotes and constitute most
of the recognized clinical cases. One study in Sweden of
306 people with the Leiden mutation showed that by age
33, 40% of Leiden homozygotes had a thrombotic event,
whereas only 20% of heterozygotes did.10 Data from the
Leiden Thrombophilia Study demonstrated that FVL pa-
tients have an overall 6.6-fold increased risk of thrombosis
compared with the general population, with homozygotes
having significantly increased risk compared to heterozy-
gotes.11
Numerous studies have attempted to determine the
prevalence of FVL. Estimates vary between 1% and 8% of
the population, with greater prevalence in Caucasians. One
cross-sectional study of 4407 people reported its presence
in 5.27% of Caucasians, compared with 1.27% of Hispanics,
1.23% of blacks, and 0.45% of Asians.12 The greatest FVL
prevalence appears to occur in people of Greek, Swedish, or
Lebanese descent.
Despite a lack of definitive prevalence data, FVL is
thought to be the most commonly inherited hypercoagu-
lable disorder. The next most prevalent disorder, protein C
deficiency, is less than half as common as FVL, occurring in
an estimated one in 200 people.13 Other thrombophilic
disorders include antithrombin III deficiency, which occurs
in an estimated one in 300 people,14 and protein S defi-
ciency, which occurs in 0.13% of the population.15
Despite greater prevalence, however, the risk of throm-
bosis as a result of FVL is much smaller than the risk
associated with other inherited thrombophilias. In an Ital-
ian study, the lifetime relative risk of a venous or arterial
thrombotic event, compared with the general population,
was only increased 2.2-fold for FVL patients. The same risk
for patients with protein C deficiency was increased 7.3-
fold, for antithrombin deficiency patients 8.1-fold, and forthose with protein S deficiency, the increased risk was
8.5-fold.6
It was previously believed that the FVL disorder, defi-
ciencies in protein S or protein C, and antithrombin III
deficiency were unique disorders with independent genetic
etiologies. Recent studies have begun to demonstrate an
inter-relationship among these conditions. For example, a
study of families with protein S deficiency found that 39% of
subjects also carried the FVL mutation.16 In another study,
18 of 128 families (15%) with antithrombin deficiency were
also FVL carriers.17 All inherited thrombophilic disorders
have not yet been linked to a single genetic locus. From a
clinical standpoint, however, patients diagnosed with one
thrombophilic defect clearly have greater risk for carrying a
second.
It appears that for patients who carry more than one
thrombophilic defect, the risk of thromboembolism is in-
creased synergistically. In an analysis of eight case-control
studies examining the effect of FVL and prothrombin
20210A defect, the odds ratio for patients heterozygous for
FVL and prothrombin mutation was 4.9 and 3.8, respec-
tively. However, the odds ratio for patients with both
disorders was 20.0, far larger than even the sum of each
individual risk.18 The synergistic effect seen with multiple
thrombophilic conditions is particularly germane to this
case report. One factor increasing the risk of recurrent
thrombotic events in this case was likely the patient’s hy-
perhomocysteinemia.
High plasma homocysteine levels are associated with
fatal and nonfatal cardiovascular events and are a modest
predictor of both coronary artery disease, stroke, and symp-
tomatic peripheral vascular disease.19-20 In addition, hyper-
homocysteinemia increases the mortality risk of patients
with peripheral vascular disease: a recent large study dem-
onstrated a 6.6-fold increase in premature mortality in
patients with both peripheral vascular disease and hyperho-
mocysteinemia compared with the absence of these condi-
tions.21 Hyperhomocysteinemia and FVL disorder are also
both associated with thromboembolism, with a synergistic
increase in hypercoagulability when present in the same
patient. A prospective study of 800 men followed for 10
years demonstrated a relative risk of venous thromboembo-
lism (VTE) of 3.6 for FVL patients, 3.4 for patients with
hyperhomocysteinemia, and 21.8 for those carrying both
traits.22
Although the relationship between hyperhomocys-
teinemia and thrombosis is apparent, the mechanism is less
clear. Hypotheses include smooth muscle cell proliferation,
oxidative stress, nitric oxide suppression, and increased
leukocyte recruitment.23-26 Among the many pathways
homocysteine appears to affect, one of the most prominent
is stimulation of the prothrombotic capacity of factor V.27
People with FVL, such as the patient reported here, have
diminished ability to regulate factor Va and thus may be
particularly vulnerable to high serum homocysteine levels.
In addition, the role of homocysteine-induced endothelial
damage in localized areas of peripheral arterial disease,
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clarified.28
CONCLUSION
FVL is a relatively new disease. The mechanisms by
which the FVL mutation disrupts coagulation and hemo-
stasis are still being explored. No clear association has been
found in the literature between FVL and arterial thrombo-
sis, but there have been case reports of arterial thrombi in
FVL patients.29-32 Some of these cases describe association
with other factors that predispose a patient to thrombosis,
such as presence of lupus anticoagulant, and the postoper-
ative period.33-35 We report a patient with FVL and several
predisposing factors for arterial thrombosis, including hy-
perhomocysteinemia, peripheral vascular disease, and
smoking. Additional research is needed to understand the
interaction of these additional factors with mutated factor
V that predispose patients to arterial thrombosis.
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